With Celgene Acquisition Closed, Bristol Faces Major Milestones

 
• By Mandy Jackson
  
Business teamwork puzzle pieces.
The $76bn merger adds significantly to Bristol's late-stage R&D pipeline. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business